347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial

Ira Winer; Lucy Gilbert; Ulka Vaishampayan; Seth Rosen; Christopher Hoimes; Jameel Muzaffar; Anna Spreafico; David McDermott; Quincy Chu; Olivier Dumas; Aman Chauhan; Arvind Chaudhry; Piotr Tomczak; Valentina Boni; Debora Bruno; Kelly Curtis; Yan Wang; Elizabeth Dorn; Jessicca Rege; Yangchun Du; Ilda Bidollari; Lei Sun; Emily Putiri; Heather Losey; Bruce Dezube; Marc Ernstoff; Vamsidhar Velcheti; James Strauss

doi:10.1136/jitc-2020-SITC2020.0347

Citation Tools

Regular and young investigator award abstracts

Clinical trials in progress

347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Winer I, Gilbert L, Vaishampayan U, et al

347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial

Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0347

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password